Table 2.
Gene Symbol | Gene Name | Expression in ICC 1 Cancer Tissues (p-Value) |
Correlation with ITGA6 (p-Value) | Correlation with ITGB1 (p-Value) | miR-29-3p Binding Site | Reference |
---|---|---|---|---|---|---|
SP1 | Sp1 transcription factor | <0.01 | <0.01 | <0.01 | + | [24,25] |
CREB1 | cAMP responsive element binding protein 1 | <0.01 | <0.01 | <0.01 | − | [25] |
MAX | MYC associated factor X | <0.01 | <0.01 | 0.011 | − | [25] |
FHL2 | four and a half LIM domains 2 | <0.01 | <0.01 | <0.01 | − | [25] |
RFX1 | regulatory factor X, 1 (influences HLA class II expression) | <0.01 | <0.01 | <0.01 | − | [25] |
HIF1A | hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | <0.01 | <0.01 | 0.019 | − | [25] |
TFAP2A | transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) | <0.01 | N.S | <0.01 | − | [25] |
CUX1 | cut-like homeobox 1 | <0.01 | <0.01 | N.S | − | [25] |
USF1 | upstream transcription factor 1 | <0.01 | N.S | <0.01 | − | [25] |
TFAP2C | transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma) |
<0.01 | N.S | N.S | + | [25] |
FOXM1 | forkhead box M1 | <0.01 | N.S | N.S | − | [26] |
SPI1 | Spi-1 proto-oncogene | <0.05 | N.S | N.S | − | [25] |
MXI1 | MAX interactor 1, dimerization protein | N.S 2 | 0.011 | N.S | + | [25] |
PAX6 | paired box 6 | N.S | <0.01 | <0.01 | − | [25] |
ESR1 | estrogen receptor 1 | N.S | 0.015 | <0.01 | − | [25] |
MEF2A | myocyte enhancer factor 2A | N.S | <0.01 | 0.038 | − | [25] |
HOXD3 | homeobox D3 | N.S | 0.012 | N.S | − | [25] |
MYC | MYC proto-oncogene, bHLH transcription factor |
N.S | N.S | N.S | − | [25] |
1 Intrahepatic cholangiocarcinoma, 2 No significant difference.